U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H21I6N5O8
Molecular Weight 1268.8791
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOXAGLIC ACID

SMILES

CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC2=C(I)C(C(=O)NCCO)=C(I)C(C(O)=O)=C2I)=C1I

InChI

InChIKey=TYYBFXNZMFNZJT-UHFFFAOYSA-N
InChI=1S/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)

HIDE SMILES / InChI
Molecular Formula C24H21I6N5O8
Molecular Weight 1268.8791
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6999377 | https://www.ncbi.nlm.nih.gov/pubmed/21414657 | https://www.drugs.com/pro/hexabrix.html | https://www.ncbi.nlm.nih.gov/pubmed/2022451 | https://www.ncbi.nlm.nih.gov/pubmed/11271894

Ioxaglate Sodium Meglumine (trade name Hexabrix) is a new low osmolality ionic contrast agent, that used as a diagnostic radiopaque medium. Following intravascular injection, Ioxaglate Sodium Meglumine is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine. The joint spaces as well as the uterus and fallopian tubes may be visualized by the direct injection of the contrast medium into the region to be studied. The usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). The doses may be repeated as necessary Patients may have clinically insignificant ECG changes during the procedure. The following adverse effects have occurred in conjunction with the administration of iodinated intravascular contrast agents for this procedure: hypotension, shock, anginal pain, myocardial infarction, cardiac arrhythmias (bradycardia, ventricular tachycardia, ventricular fibrillation) and cardiac arrest.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Disruption in the BBB, such as occurs in malignant tumors of the brain, allows accumulation of contrast medium within the interstitial tumor tissue; adjacent normal brain tissue does not contain the contrast medium.

Originator

Guerbet
26
Curator's Comment: Hexabrix® was first marketed in 1979 in France. Guerbet markets Hexabrix® in Japan (1978) and in the USA (1985)

Approval Year

1985
117
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8583
HEXABRIX

Approved Use

INDICATIONS AND USAGE.

Launch Date

1986
Diagnostic
Approved
8583
HEXABRIX

Approved Use

INDICATIONS AND USAGE. HEXABRIX is indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, intravenous digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography.

Launch Date

1986
Diagnostic
Approved
8583
HEXABRIX

Approved Use

INDICATIONS AND USAGE. HEXABRIX is indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, intravenous digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography.

Launch Date

1986
Diagnostic
Approved
8583
Hexabrix

Approved Use

Coronary Angiography

Launch Date

1985
Diagnostic
Approved
8583
Hexabrix

Approved Use

Cerebral angiography

Launch Date

1985
Diagnostic
Approved
8583
Hexabrix

Approved Use

Peripheral venography (phlebography)

Launch Date

1985
Diagnostic
Approved
8583
Hexabrix

Approved Use

arthrography

Launch Date

1985
Diagnostic
Approved
8583
Hexabrix

Approved Use

excretory urography

Launch Date

1985
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2100 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
26.663 g single, intravenous
dose: 26.663 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IOXAGLIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
92 min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
26.663 g single, intravenous
dose: 26.663 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IOXAGLIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Other AEs: Chest pain, Nausea...
Other AEs:
Chest pain (grade 1-2, 4.4%)
Nausea (grade 1-2, 6.4%)
Vomiting (grade 1-2, 1.6%)
Allergic skin reaction (grade 1-2, 5.2%)
Bronchospasm (grade 3, 0.8%)
Warmth (grade 1-2, 4.4%)
Bad taste (grade 1-2, 0.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
194.8 mL single, intravenous
Recommended
Dose: 194.8 mL
Route: intravenous
Route: single
Dose: 194.8 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/16949481
unhealthy, 68.7+/-7.5
Health Status: unhealthy
Age Group: 68.7+/-7.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16949481
Other AEs: Nephropathy...
Other AEs:
Nephropathy (17%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16949481
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Other AEs: Cyanosis, Bradycardia...
Other AEs:
Cyanosis (grade 3-5)
Bradycardia (grade 3-5)
Acidosis (grade 3-5)
Pulmonary hemorrhage (grade 3-5)
Convulsions (grade 3-5)
Coma (grade 4-5)
Cardiac arrest (grade 4-5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Bad taste grade 1-2, 0.4%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Vomiting grade 1-2, 1.6%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Chest pain grade 1-2, 4.4%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Warmth grade 1-2, 4.4%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Allergic skin reaction grade 1-2, 5.2%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Nausea grade 1-2, 6.4%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Bronchospasm grade 3, 0.8%
101 mL single, intraarterial
Recommended
Dose: 101 mL
Route: intraarterial
Route: single
Dose: 101 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
unhealthy, 59+/-11
Health Status: unhealthy
Age Group: 59+/-11
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/1552109
Nephropathy 17%
194.8 mL single, intravenous
Recommended
Dose: 194.8 mL
Route: intravenous
Route: single
Dose: 194.8 mL
Sources:
https://pubmed.ncbi.nlm.nih.gov/16949481
unhealthy, 68.7+/-7.5
Health Status: unhealthy
Age Group: 68.7+/-7.5
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/16949481
Acidosis grade 3-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Bradycardia grade 3-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Convulsions grade 3-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Cyanosis grade 3-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Pulmonary hemorrhage grade 3-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Cardiac arrest grade 4-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Coma grade 4-5
250 mL single, intravenous
Overdose
Dose: 250 mL
Route: intravenous
Route: single
Dose: 250 mL
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31718
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31718
eMolecules
36552946
https://www.emolecules.com/cgi-bin/more?vid=36552946
PubMed

PubMed

TitleDatePubMed
Evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in coronary angiography.
2007-04-17
Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.
2007-04-17
Iodixanol vs ioxaglate for preventing contrast nephropathy: who is winner?
2007-04
Effects of iodinated contrast media on endothelium: An in vitro study.
2007-03
Contrast agent enhanced pQCT of articular cartilage.
2007-02-21
Reactive oxygen species independent cytotoxicity induced by radiocontrast agents in tubular cells (LLC-PK1 and MDCK).
2007
Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
2006-11
Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
2006-09-05
A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients.
2006-08
Effects of different contrast media on glutathione peroxidase and superoxide dismutase activities in the heart and kidneys of normal and streptozotocin-induced diabetic rats.
2006-07
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
2006-06
The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review.
2006-04-27
Iodinated radiographic contrast media possess antioxidant properties in vitro.
2005-12
Usefulness of a new grading system based on coronary flow velocity pattern in predicting outcome in patients with acute myocardial infarction having percutaneous coronary intervention.
2005-10-01
Adverse reactions of low osmolar non-ionic and ionic contrast media when used together or separately during percutaneous coronary intervention.
2005-09
The effect of contrast media on the synovial membrane.
2005-09
N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial.
2005-06
Contrast medium attenuates platelet activation and platelet-leukocyte cross-talk.
2005-05
The effects of carbon dioxide versus ioxaglate in the rat kidney.
2005-02
Ultrasound findings of iodide mumps.
2005-02
Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol.
2005-01-15
Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
2005-01-01
Renal effects of CO2 and iodinated contrast media in patients undergoing renovascular intervention: a prospective, randomized study.
2005-01
Influence of contrast media (iopromide, ioxaglate, gadolinium-DOTA) on blood viscosity, erythrocyte morphology and platelet function.
2005
Hepatopulmonary syndrome induced by common bile duct ligation in a rabbit model: correlation between pulmonary vascular dilatation on thin-section CT and angiography and serum nitrite concentration or endothelial nitric oxide synthase (eNOS)1 expression.
2004-10-07
Similarity and difference in the acute lung injury induced by a radiographic contrast medium and an anticancer agent paclitaxel in rats.
2004-08-30
Prediction of the no-reflow phenomenon with ultrasonic tissue characterization in patients with anterior wall acute myocardial infarction.
2004-06-01
Role of osmolality of contrast media in the development of post-ERCP pancreatitis: a metanalysis.
2004-03
Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents.
2004-02
[Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography].
2003-12
No difference among modern contrast media's effect on neointimal proliferation and restenosis after coronary stenting in pigs.
2003-12
Nonionic low-osmolar contrast media have no impact on major adverse cardiac events in patients undergoing coronary stenting with appropriate antiplatelet therapy.
2003-12
Inflammatory markers increase following exposure to radiographic contrast media.
2003-09
Glaucoma as a complication of superselective ophthalmic angiography.
2003-09
Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells.
2003-08
Calcium-dependent injury of human microvascular endothelial cells induced by a variety of iodinated radiographic contrast media.
2003-06
Review article: Effects of radiographic contrast media on the lung.
2003-05
Roles of intracellular Ca2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media.
2003-04
Delayed side effects induced by iodinated contrast media, especially those associated with iodixanol.
2003-03
A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.
2003-03
Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells.
2003-03
The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets.
2003-02
In vivo comparative antithrombotic effects of ioxaglate and iohexol and interaction with the platelet antiaggregant clopidogrel.
2003-01
Differential effects of the iodinated contrast agents Ioxaglate, Iohexol and Iodixanol on thrombus formation and fibrinolysis.
2003
[Arteries of the uterine cervix in reproductive age in microangiographic studies].
2002-12
[Arteries of the hilum and parenchymal part of the ovary in reproductive age in microangiographic studies].
2002-12
[Iodic allergic reaction with vasospasm occluded coronary during coronarography].
2002-12
Effects of gentamicin, lipopolysaccharide, and contrast media on immortalized proximal tubular cells.
2002-11
Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway.
2002-11
Allergies correlated to adverse reactions induced by non-ionic monomeric and ionic dimeric contrast media for contrast enhanced CT examination.
2002-09
Patents

Patents

018905-002
4
WO2016054658
7

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Hexabrix may be administered by catheter injection into the chambers of the heart or associated large blood vessels. Hexabrix may be injected to visualize the peripheral arterial circulation. Hexabrix may be injected centrally, in either the superior or inferior vena cava or right atrium; or peripherally into an appropriate arm vein. Hexabrix may be injected to visualize the peripheral venous circulation. Venograms are obtained by injection or infusion into an appropriate vein in the upper or lower extremity.
For PEDIATRIC ANGIOCARDIOGRAPHY the usual total dose of Hexabrix per procedure, which includes diagnostic and test doses is about 4 mL/kg. This dosage may be as small as 1.5 mL/kg and should not normally exceed 5 mL/kg. For SELECTIVE CORONARY ARTERIOGRAPHY the usual adult dose for left coronary arteriography is 8 mL (range 2-14 mL) and for right coronary arteriography is 5 mL (range 1-10 mL). For PHLEBOGRAPHY the dose for adults will usually range from 50-100 mL per extremity of full strength (32% iodine) Hexabrix as a single rapid injection.
Route of Administration: Intravascular
In Vitro Use Guide
Bovine patellar cartilage samples were immersed in 21 mM Hexabrix (Ioxaglic Acid) solution for 24 hours to be successfully scanned with a clinical pQCT instrument.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:56:12 GMT 2025
Edited
by admin
on Mon Mar 31 17:56:12 GMT 2025
Record UNII
Z40X7EI2AF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IOXAGLIC ACID
EP   INN   JAN   MART.   MI   USAN   USP   USP-RS   WHO-DD  
INN   USAN  
Official Name English
IOXAGLATE
VANDF  
Preferred Name English
Ioxaglic acid [WHO-DD]
Common Name English
IOXAGLIC ACID [MI]
Common Name English
IOXAGLIC ACID [USP-RS]
Common Name English
N-(2-Hydroxyethyl)-2,4,6-triiodo-5-[2-[2,4,6-triiodo-3-(N-methylacetamido)-5-(methylcarbamoyl)benzamido]acetamido]isophthalamic acid
Systematic Name English
P-286
Code English
ioxaglic acid [INN]
Common Name English
IOXAGLIC ACID [USAN]
Common Name English
HEXABRIX 320
Brand Name English
IOXAGLIC ACID [MART.]
Common Name English
IOXAGLIC ACID [EP MONOGRAPH]
Common Name English
IOXAGLIC ACID [JAN]
Common Name English
BENZOIC ACID, 3-((((3-(ACETYLMETHYLAMINO)-2,4,6-TRIIODO-5-9((METHYLAMINO)CARBONYL)BENZOYL)AMINO)ACETYL)AMINO)-5-(((2-HYDROXYETHYL)AMINO)CARBONYL)-2,4,6-TRIIODO-
Common Name English
IOXAGLIC ACID [USP MONOGRAPH]
Common Name English
IOXAGLATE [VANDF]
Common Name English
Classification Tree Code System Code
NDF-RT N0000180185
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
NCI_THESAURUS C28500
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
WHO-ATC V08AB03
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
WHO-VATC QV08AB03
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
NDF-RT N0000010258
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
Code System Code Type Description
INN
4217
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
LACTMED
Ioxaglate
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
ECHA (EC/EINECS)
261-560-1
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
EVMPD
SUB08264MIG
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
RS_ITEM_NUM
1345159
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
CHEBI
31718
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023166
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
RXCUI
1426458
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
HSDB
8077
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
PUBCHEM
3742
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
USAN
T081
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
SMS_ID
100000083116
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
WIKIPEDIA
Ioxaglic acid
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
DRUG BANK
DB09313
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
MESH
D007485
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
FDA UNII
Z40X7EI2AF
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
DRUG CENTRAL
1472
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
NCI_THESAURUS
C61793
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
CAS
59017-64-0
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY
MERCK INDEX
m6380
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
PRIMARY Merck Index
RXCUI
5973
Created by admin on Mon Mar 31 17:56:12 GMT 2025 , Edited by admin on Mon Mar 31 17:56:12 GMT 2025
ALTERNATIVE
Related Record Type Details
Structure of IOXAGLATE MEGLUMINE
SALT/SOLVATE -> PARENT
Structure of IOXAGLATE SODIUM MEGLUMINE
SALT/SOLVATE -> PARENT
Structure of IOXAGLATE SODIUM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 3-[[[[3-(Acetylmethylamino)-5-(dimethylcarbamoyl)-2,4,6-triiodobenzoyl]amino]acetyl]amino]-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-[[[[3-(Acetylmethylamino)-2,6-diiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((((3-(ACETYLMETHYLAMINO)-2,4,6-TRIIODO-5-(METHYLCARBAMOYL)BENZOYL)AMINO)ACETYL)AMINO)-5-((2-(ACETYLOXY)ETHYL)CARBAMOYL)-2,4,6-TRIIODOBENZOIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-AMINO-5-(((2-HYDROXYETHYL)AMINO)CARBONYL)-2,4,6-TRIIODOBENZOIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3,3?-[[5-(Acetylmethylamino)-2,4,6-triiodo-1,3-phenylene]bis(carbonyliminomethylenecarbonylimino)]bis[5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic] acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-[[[[3-[[[[3-(Acetylmethylamino)-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoyl]amino]acetyl]amino]-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of IOXAGLIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966